安罗替尼-话题@MedSci

#安罗替尼#

11篇内容 | 4376人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1241541, encodeId=521c1241541fa, content=<a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>联合<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>治疗PD-L1阳性晚期<a href='/topic/show?id=146246308d1' target=_blank style='color:#2F92EE;'>#宫颈癌#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, objectType=article, longId=299549, objectId=91b029954956, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022223/1645621460454_2110107.JPG, objectUrl=/article/show_article.do?id=91b029954956, replyNumber=0, likeNumber=185, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b029954956, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b029954956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1218141, encodeId=e62b1218141d7, content=<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>, objectTitle=安罗替尼超说明书用药专家共识, objectType=guider, longId=15784, objectId=b354a1c00231a570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=b354a1c00231a570, replyNumber=0, likeNumber=146, createdTime=2022-05-09, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b354a1c00231a570, moduleTitle=安罗替尼超说明书用药专家共识, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=b354a1c00231a570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1214249, encodeId=dbca12142491a, content=<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, objectType=article, longId=299549, objectId=91b029954956, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022223/1645621460454_2110107.JPG, objectUrl=/article/show_article.do?id=91b029954956, replyNumber=0, likeNumber=139, createdTime=2022-04-25, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b029954956, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b029954956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1214248, encodeId=f2f812142489e, content=<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>, objectTitle=Thorac Cancer：Anlotinib（安罗替尼）治疗小细胞肺癌伴有胸腔积液患者的疗效和安全性, objectType=article, longId=221642, objectId=5305221642d2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021126/1638796262065_1611618.PNG, objectUrl=/article/show_article.do?id=5305221642d2, replyNumber=0, likeNumber=128, createdTime=2022-04-25, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5305221642d2, moduleTitle=Thorac Cancer：Anlotinib（安罗替尼）治疗小细胞肺癌伴有胸腔积液患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5305221642d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=971341, encodeId=84349e134167, content=<a href='/topic/show?id=bec66989e9a' target=_blank style='color:#2F92EE;'>#甲状腺癌#</a>采用<a href='/topic/show?id=4399103e93a7' target=_blank style='color:#2F92EE;'>#抗血管新生#</a>治疗效果是不错的，<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>是其中之一。, objectTitle=Br J Cancer：安罗替尼通过靶向EGFR抑制未分化甲状腺癌的血管生成作用, objectType=article, longId=212378, objectId=98962123e86a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202166/1622971531435_2467676.PNG, objectUrl=/article/show_article.do?id=98962123e86a, replyNumber=0, likeNumber=274, createdTime=2021-06-06, rootId=0, userName=小小医者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98962123e86a, moduleTitle=Br J Cancer：安罗替尼通过靶向EGFR抑制未分化甲状腺癌的血管生成作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98962123e86a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=904239, encodeId=489a904239e2, content=<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>治疗晚期<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a>，这算是<a href='/topic/show?id=bdeb1040e072' target=_blank style='color:#2F92EE;'>#软文#</a>吧, objectTitle=盐酸安罗替尼治疗晚期肺癌中国专家共识（2020版）, objectType=guider, longId=12841, objectId=d63761c002020205, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=d63761c002020205, replyNumber=0, likeNumber=259, createdTime=2020-12-02, rootId=0, userName=lifefamily@163, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d63761c002020205, moduleTitle=盐酸安罗替尼治疗晚期肺癌中国专家共识（2020版）, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=d63761c002020205)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=897980, encodeId=6a3c89e980be, content=<a href='/topic/show?id=341f25314f1' target=_blank style='color:#2F92EE;'>#仑伐替尼#</a>治疗<a href='/topic/show?id=bec66989e9a' target=_blank style='color:#2F92EE;'>#甲状腺癌#</a>，其它的如<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>也激烈竞争, objectTitle=国家药监局批准卫材仑伐替尼治疗甲状腺癌，这是第二个适应症, objectType=article, longId=203201, objectId=fb9120320195, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20201019/d078912376a94915ad074255717454ba.jpg, objectUrl=/article/show_article.do?id=fb9120320195, replyNumber=0, likeNumber=342, createdTime=2020-11-09, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb9120320195, moduleTitle=国家药监局批准卫材仑伐替尼治疗甲状腺癌，这是第二个适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb9120320195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=897972, encodeId=04a389e97276, content=<a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a>如果能联合抗血管新生，如<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>，或<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>或<a href='/topic/show?id=196b9e808ed' target=_blank style='color:#2F92EE;'>#阿帕替尼#</a>，估计效果会更好！！，值得探索这样的组合。另外，对于<a href='/topic/show?id=56b0194220e' target=_blank style='color:#2F92EE;'>#一线治疗#</a>，以及后续<a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>的探索，再结合不同的突变亚型，可能会更佳！, objectTitle=NEJM：Niraparib一线治疗晚期卵巢癌, objectType=article, longId=184964, objectId=1d621849647a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201912/20191219180232727.jpg, objectUrl=/article/show_article.do?id=1d621849647a, replyNumber=0, likeNumber=342, createdTime=2020-11-09, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d621849647a, moduleTitle=NEJM：Niraparib一线治疗晚期卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d621849647a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=897970, encodeId=b8f889e97047, content=<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>，绝佳搭配！不过，<a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a>如果联合贝伐单抗或<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>，估计效果也不错, objectTitle=NEJM：奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌, objectType=article, longId=184966, objectId=1d4b184966ae, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201912/20191219183629999.jpg, objectUrl=/article/show_article.do?id=1d4b184966ae, replyNumber=0, likeNumber=301, createdTime=2020-11-09, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d4b184966ae, moduleTitle=NEJM：奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d4b184966ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

安罗替尼

2020-05-29

循证小兵

#信迪利单抗#联合#安罗替尼#治疗PD-L1阳性晚期#宫颈癌#

J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌

2022-08-28

病毒猎手

#安罗替尼#

安罗替尼超说明书用药专家共识

2022-05-09

病毒猎手

#安罗替尼#

J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌

2022-04-25

病毒猎手

#安罗替尼#

Thorac Cancer：Anlotinib（安罗替尼）治疗小细胞肺癌伴有胸腔积液患者的疗效和安全性

2022-04-25

小小医者

#甲状腺癌#采用#抗血管新生#治疗效果是不错的，#安罗替尼#是其中之一。

Br J Cancer：安罗替尼通过靶向EGFR抑制未分化甲状腺癌的血管生成作用

2021-06-06

lifefamily@163

#安罗替尼#治疗晚期#肺癌#，这算是#软文#吧

盐酸安罗替尼治疗晚期肺癌中国专家共识（2020版）

2020-12-02

lovetcm

#仑伐替尼#治疗#甲状腺癌#，其它的如#安罗替尼#也激烈竞争

国家药监局批准卫材仑伐替尼治疗甲状腺癌，这是第二个适应症

2020-11-09

lovetcm

#尼拉帕利#如果能联合抗血管新生，如#贝伐单抗#，或#安罗替尼#或#阿帕替尼#，估计效果会更好！！，值得探索这样的组合。另外，对于#一线治疗#，以及后续#维持治疗#的探索，再结合不同的突变亚型，可能会更佳！

NEJM：Niraparib一线治疗晚期卵巢癌

2020-11-09

lovetcm

#奥拉帕利#联合#贝伐单抗#，绝佳搭配！不过，#尼拉帕利#如果联合贝伐单抗或#安罗替尼#，估计效果也不错

NEJM：奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌

2020-11-09